Varamir
Desk
News
Calendar
Pricing
Saved
Search
tickers or companies
⌘K
Start free
· no card
Sign in
AURA compared with NAMS: revenue, margins and what each company keeps, and the suppliers and customers both name
AURA
Aura Biosciences, Inc.
Change
Mkt cap
Revenue
Revenue
NAMS
NewAmsterdam Pharma Co N.V.
Change
Mkt cap
Revenue
Revenue
vs
Compare
AURA
Aura Biosciences, Inc.
vs
NAMS
NewAmsterdam Pharma Co N.V.
Price
Mkt cap
Revenue
Revenue
Change
Change
Revenue flow
Supply chain
Price
Co-movers
Event sensitivity
Earnings history
Save comparison
Copy link
Revenue flow
Desk
News
Calendar
Saved
Search
AURA
Aura Biosciences, Inc.
Change
6.03
▼
−1.87%
· post 6.03
Mkt cap
$636.7M
Revenue
—
Revenue
—
NAMS
NewAmsterdam Pharma Co N.V.
Change
19.57
▼
−2.43%
· post 19.57
Closed
Nov 2 '26
Mkt cap
$2.4B
Revenue
$4M
Q2 FY26
Revenue
$23M
FY25
vs
Compare
Closed
Nov 2 '26
AURA
Aura Biosciences, Inc.
vs
NAMS
NewAmsterdam Pharma Co N.V.
6.03
▼
−1.87%
post 6.03
Price
19.57
▼
−2.43%
post 19.57
$636.7M
Mkt cap
$2.4B
—
Revenue
$4M
Q2 FY26
—
Revenue
$23M
FY25
Change
Change
AURA
6.03
▼
−1.87%
vs
NAMS
19.57
▼
−2.43%
Closed
Nov 2 '26
Revenue flow
Supply chain
Price
Co-movers
Event sensitivity
Earnings history
Price
rebased to 0%
1D
1W
1M
3M
YTD
1Y
5Y
1D
1W
1M
3M
YTD
1Y
5Y
AURA, solid
NAMS, dashed
Supply-chain overlap
Revenue flow
AURA: latest quarter not drawable. NAMS: latest quarter is a loss; flow not drawable.
Method
›
Supply-chain overlap
direct ties · both sides
Sources
›
direct ties · both sides
No disclosed counterparties: AURA, NAMS.
Role chip = supplier or customer
Source: SEC EDGAR